Phase 2 and 3 studies of thalidomide-dexamethasone and triplet thalidomide-based combinations in preparation for ASCT
| Regimen . | N . | After induction . | After ASCT . | PFS . | OS . | Reference . | ||
|---|---|---|---|---|---|---|---|---|
| CR + PR, % . | CR/ ≥ VGPR, % . | CR + PR, % . | CR/ ≥ VGPR, % . | |||||
| TD vs | 100 | 76 | 10/19 | NR | NR | NR | NR | 42 |
| VAD (retrospective case-matched study) | 100 | 52 | 8/14 | NR | NR | NR | NR | |
| TD vs | 103 | 63 | 4/NR | NR | NR | NR | NR | 44 |
| VAD | 104 | 41 | 0/NR | NR | NR | NR | NR | |
| TD vs | 100 | 66 | NR/35 | 68 | NR/44 | NR | NR | 43 |
| Descamethasone | 104 | 52 | NR/13 | 62 | NR/42 | NR | NR | |
| TAD vs | 268 | 71 | 3/37 | 84 | 14/54 | median, 34 mo | median, 73 mo | 47 |
| VAD | 268 | 57 | 2/18 | 76 | 12/44 | median, 22 mo | median, 60 mo | |
| P < .001 | P = .77 | |||||||
| CTD vs | NR | 87 | 19/NR | NR | 51/NR | NR | NR | 48 |
| CVAD | NR | 75 | 9/NR | NR | 40/NR | NR | NR | |
| TT2 + THAL vs | 323 | NR | NR | NR | 62/NR | 5-yr, 56% | 5-yr, 65% | 46 |
| TT2 without THAL | 345 | NR | NR | NR | 43/NR | 5-yr, 44% | 5-yr, 65% | |
| P = .01 | P = .90 | |||||||
| Double ASCT + THAL vs | 135 | NR | NR/30 | NR | NR/68 | 4-yr, 51% | 5-yr, 69% | 45 |
| Double ASCT without THAL (retrospective case-matched study) | 135 | NR | NR/15 | NR | NR/49 | 4-yr, 31% | 5-yr, 53% | |
| P = .001 | P = .07 | |||||||
| Regimen . | N . | After induction . | After ASCT . | PFS . | OS . | Reference . | ||
|---|---|---|---|---|---|---|---|---|
| CR + PR, % . | CR/ ≥ VGPR, % . | CR + PR, % . | CR/ ≥ VGPR, % . | |||||
| TD vs | 100 | 76 | 10/19 | NR | NR | NR | NR | 42 |
| VAD (retrospective case-matched study) | 100 | 52 | 8/14 | NR | NR | NR | NR | |
| TD vs | 103 | 63 | 4/NR | NR | NR | NR | NR | 44 |
| VAD | 104 | 41 | 0/NR | NR | NR | NR | NR | |
| TD vs | 100 | 66 | NR/35 | 68 | NR/44 | NR | NR | 43 |
| Descamethasone | 104 | 52 | NR/13 | 62 | NR/42 | NR | NR | |
| TAD vs | 268 | 71 | 3/37 | 84 | 14/54 | median, 34 mo | median, 73 mo | 47 |
| VAD | 268 | 57 | 2/18 | 76 | 12/44 | median, 22 mo | median, 60 mo | |
| P < .001 | P = .77 | |||||||
| CTD vs | NR | 87 | 19/NR | NR | 51/NR | NR | NR | 48 |
| CVAD | NR | 75 | 9/NR | NR | 40/NR | NR | NR | |
| TT2 + THAL vs | 323 | NR | NR | NR | 62/NR | 5-yr, 56% | 5-yr, 65% | 46 |
| TT2 without THAL | 345 | NR | NR | NR | 43/NR | 5-yr, 44% | 5-yr, 65% | |
| P = .01 | P = .90 | |||||||
| Double ASCT + THAL vs | 135 | NR | NR/30 | NR | NR/68 | 4-yr, 51% | 5-yr, 69% | 45 |
| Double ASCT without THAL (retrospective case-matched study) | 135 | NR | NR/15 | NR | NR/49 | 4-yr, 31% | 5-yr, 53% | |
| P = .001 | P = .07 | |||||||
Studies incorporating thalidomide-dexamethasone throughout double ASCT are also included.
CTD indicates cyclophosphamide, thalidomide, dexamethasone; CVAD, cyclophosphamide added to VAD (vincristine, doxorubicin, dexamethasone); NR, not reported; TAD, thalidomide, doxorubicin, dexamethasone; TD, thalidomide, dexamethasone; THAL, thalidomide; and TT2, Total Therapy 2.